First-Line Dabrafenib plus Trametinib Has Activity in BRAFV600E NSCLC [Clinical Trials]

Dabrafenib plus trametinib achieves responses in 64% of patients with metastatic BRAFV600E NSCLC.
Source: Cancer Discovery - Category: Cancer & Oncology Tags: Clinical Trials Source Type: research